Article history: Received: 24-05-2017, Accepted: 29-08-2017, Published online: 20-09-2017
Corresponding author: Faten A. M. Abo-Aziza
E-mail: firstname.lastname@example.orgCitation: Abo-Aziza FAM, Zaki AA, El-Shemy A, Abd Elhalem SS and Amer AS (2017) Immunological and histopathological changes in sheep affected with cutaneous squamous cell carcinoma and treated immunotherapeutically, Veterinary World, 10(9): 1094-1103.
Background and Aim: Recently, it has been recorded unexpected percentage of cutaneous squamous cell carcinoma (cSCC) in sheep. Despite the improvement in surgical treatment, the outcome of animals remains limited by metastatic relapse. Although antibodies for cancer treatment have been practiced for many decades, the use of this methodology in animals is deficient. This study aimed to establish cSCC therapy by tumor cell protein antibody (Ab1) or secondary antibody (Ab2) raised by two series of immunization in the same strain of rabbits.
Materials and Methods: A total of 19 Ossimi sheep were used (14 sheep suffered from cSCC and 5 were apparently healthy). Each animal from control healthy group (n=5) and control cSCC (n=4) group was treated with a course of eight injections of normal globulins. Animals in the third (n=5) and the last (n=5) groups received a course of eight injections of Ab1and Ab2, respectively. Each tumor was measured before and after treatment. The eight injections were applied at 1st, 3rd, 5th, 7th, and 9th week and the remaining three injections were at 1 week interval. Tissue specimens and blood samples were taken for histological and immunological studies.
Results: The obtained results revealed that injection of Ab1 might prevent the bad prognostic picture of polymorph infiltration without any criteria of regression % of tumor. Treatment with Ab2 showed regression of tumor size ranged between minimum of 8.99% and maximum of 78.12%, however, the measurements in most cases reached the maximum regression after the past two injections. In additions, infiltration of lymphocytes to tumor site, normalization of leukocytes picture and also increase of antibody titer were observed.
Conclusion: This profile might confirm that Ab2 could act as an antigen and encourage us to use it as a tumor vaccine. Extensive studies are needed to isolate the idiotypic portion of Ab1 for raising Ab2 as an anti-idiotypic antibody to be used as tumor vaccine. The question of how lymphocyte traffic to the tumor site as a result of Ab2 injection needs further investigation.
Keywords: antibody, cutaneous squamous cell carcinoma, histopathology, immunotherapy, sheep.
1. Valentine, B.A., Neoplasia, I.N., Fubini, S.L. and Ducharme, N.G. (2004) In: Fubini, S.L. and Ducharme, N.G., editors. Farm Animal Surgery. Saunders, USA.
2. Ahmed, A.F. and Hassanein, K.M.A. (2012) Ovine and caprine cutaneous and ocular neoplasms. Small Rum. Res., 106: 189-200. [Crossref]
3. Najarnezhad, V. and Aslani, M.R. (2012) Unusual case of cutaneous squamous cell carcinoma in an ewe. Iran. J. Vet. Sci. Technol., 4: 49-53.
4. Tmumen, S.K., Al-Azreg, S.A., Abushhiwa, M.H., Alkoly, M.A., Bennour, E.M. and Al-Attar, S.R. (2016) Cutaneous squamous cell carcinoma in the lateral abdominal wall of local Libyan ewes. Open Vet. J., 6(2): 139-142. [Crossref] [PubMed] [PMC]
6. Almahroos, M. and Kurban, A. (2007) Ultraviolet carcinogenesis in non-melanoma skin cancer. Part I: Incidence rates in relation to geographic locations and in migrant populations. Skin Med. Dermatol. Clin., 3(1): 29-35.
7. Ginn, P.E., Mansell, J.E.K.L. and Rakich, P.M. (2007) Skin and appendages. In: Jubb, K.V.F., Kennedy, P.C., Palmer, N.C., editors. Pathology of the Domestic Animals. 5th ed. Elsevier Saunders, Philadelphia, PA.
8. Yamashiro, Y., Takei, K., Umikawa, M., Asato, T., Oshiro, M., Uechi, Y., Ishikawa, T., Taira, K., Uezato, H. and Kariya, K. (2010) Ectopic coexpression of keratin 8 and 18 promotes invasion of transformed keratinocytes and is induced in patients with cutaneous squamous cell carcinoma. Biochem. Biophys. Res. Commun., 399(3): 365-372. [Crossref] [PubMed]
9. Webb, J.L., Burns, R.E., Brown, H.M., Leroy, B.E. and Kosarek, C.E. (2009) Squamous cell carcinoma. Compend. Contin. Educ. Vet., 31: 133-142.
10. Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G. and Posey, L. (1999) Pharmacotherapy: A Pathophysiologic Approach. 4th ed., Vol. 21. Appleton & Lange, Stamford, CT. p81-95.
11. Fridman, W.H., Pages, F., Sautes-Fridman, C. and Galon, J. (2012) The immune contexture in human tumours: Impact on clinical outcome. Nat. Rev. Cancer, 12: 298-306. [Crossref]
12. Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H. and Trajanoski, Z. (2017) Pan-cancer immunogenic analyses reveals genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell. Rep., 18: 248-262. [Crossref] [PubMed]
13. Raval, R.R., Andrew, B.S., Amanda, J.W., Charles, G.D. and Sharma, P. (2014) Tumor immunology and cancer immunotherapy: Summary of the 2013 SITC primer. J. Immunother. Cancer, 2: 14. [Crossref]
15. Roberto, E.G. and Maria, L.A. (2012) Anti-idio type antibodies in cancer treatment: The pharmaceutical industry perspective. Front. Oncol., 2(147): 1-4.
16. Jun, M.H., Johnson, R.H., Maguire, D.J. and Hopkins, P.S. (1978) Enhancement and metastasis after immunotherapy of ovine squamous-cell carcinoma. Br. J. Cancer, 38: 382-391. [Crossref]
17. Boguslawa, B., Ewa, W., Witort, M.C., Lidia, M. and Agnieszka, B.B. (2003) Direct effects of cocaine-amphetamine-regulated transcript (CART) on pituitary hormone release in pituitary cell culture. Neuroendocrinol. Lett., 24: 224-226.
18. Philip, H. and Noboru, S. (1980) Antisera inhibiting mammalian cell spreading and possible cell surface antigens involved. J. Cell. Biol., 86: 866-873. [Crossref]
19. Sadeek, L.A. (1998) Studies on Physiological Safety of Rinderpest Vaccine in Sheep. Ph.D. Thesis Faculty of Veterinary Medicine, Cairo University.
21. Bancroft, J.D., Layton, C. and Suvarna, S.K. (2013) Bancroft's Theory and Practice of Histological Techniques. 7th ed. Churchill Livingstone, Elsevier. p151.
22. Hernandez, A.M., Toledo, D., Martinez, D., Gri-an, T., Brito, V., Macias, A., Alfonso, S., Rondon, T., Suarez, E., Vazquez, A.M. and Perez, R. (2008) Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti- idiotype antibody. J. Immunol., 181: 6625-6634. [Crossref]
23. Coles, E.H. (1980) Veterinary Clinical Pathology. 3rd ed. W.B. Sanders Co., Philadelphia, PA. p10-20.
24. Ghaffar, A., Ashraf, S., Hussain, R., Hussain, T., Shafique, M., Noreen, S. and Aslam, S. (2014) Clinic hematological disparities induced by triazophos (organophosphate) in Japanese quail. Pak. Vet. J., 34: 257-259.
25. Hassanein, K.M.A. and Mahmoud, A.Z. (2009) Pathological studies on tumor incidence in farm animals. Alex. J. Vet. Sci., 28: 105-117.
26. Ahmed, I.H., Helal, I.E., Al-Sobayil, F.A. and Mehana, E.E. (2007) Adenoma and adenocarcinoma in sheep and goats. Suez Canal Vet. Med. J., 12(2): 279.
27. Baniadam, A., Moezzi, N. and Mohammadian, B. (2010) Nasal squamous cell carcinoma in a cow. Turk. J. Vet. Anim. Sci., 34(3): 303-305.
28. Bendandi, M., Rodriguez-Calvillo, M., Inoges, S., Lopez-Diaz, D.E., Cerio, A., Perez-Simon, J.A., Rodriguez-Caballero, A., Garcia-Montero, A., Almeida, J., Zabalegui, N., Giraldo, P., San Miguel, J. and Orfao, A. (2006) combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk. Lymphoma, 47: 29-37. [Crossref] [PubMed]
31. Balkwill, F. and Mantovani, A. (2001) Inflammation and cancer: Back to Virchow? Lancet, 357: 539-545. [Crossref]
32. Walsh, S.R., Cook, E.J., Goulder, F., Justin, T.A. and Keeling, N.J. (2005) Neutrophil-lym-phocyte ratio as a prognostic factor in colorectal cancer. J. Surg. Oncol., 91: 181-184. [Crossref] [PubMed]
33. Koga, Y., Matsuzaki, A., Suminoe, A., Hattori, H. and Hara, T. (2004) Neutrophil-derived related apoptosis-inducing ligand (TRAIL): A novel mechanism of anti-tumor effect by neutrophils. Cancer Res., 64: 1037-1043. [Crossref]
36. Casbon, A.J., Reynaud, D., Park, C., Khuc, E., Gan, D.D., Schepers, K., Passegue, E. and Werb, Z. (2015) Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc. Natl. Acad. Sci. USA, 112: E566-E575. [Crossref]
37. Coffelt, S.B., Kersten, K., Doornebal, C.W., Weiden, J., Vrijland, K., Hau, C.S., Verstegen, N.J., Ciampricotti, M., Hawinkels, L.J. and Jonkers, J. (2015) IL17-producing gamma delta T cells and neutrophils conspire to promote breast cancer metastasis. Nature, 522: 345-348. [Crossref] [PubMed] [PMC]
38. Mellstedt, H., Frodin, J.F., Biberfeld, P., Fagerberg, J., Gisombe, R., Hernandez, A., Masucci, G., Li, S.L. and Steinitz, M. (1991) Patients treated with a monoclonal antibody (Abl) to the colorectal carcinoma antigen 17-1A develop a cellular response (DTH) to the internal image of the antigen (Ab2). Int. J. Cancer, 48: 344-349. [Crossref] [PubMed]
39. Blair, P.A., Nore-a, L.Y., Flores-Borja, F., Rawlings, D.J., David, A., Isenberg, D.A., Ehrenstein, M.R. and Mauri, C. (2010), CD19(+) CD24(hi) CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity, 32: 129. [Crossref] [PubMed]
40. Lee, H.J., Seo, J.Y., Ahn, J.H., Ahn, S.H. and Gong, G. (2013) Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J. Breast Cancer, 16(1): 32-39. [Crossref] [PubMed] [PMC]
41. Jacobsen, J.T., Lunde, E., Sundvold-Gjerstad, V., Munthe, L.A. and Bogen, B. (2010) The cellular mechanism by which complementary Id+ and anti-Id antibodies communicate: T cells integrated into idiotypic regulation. Immunol. Cell. Biol., 88: 515-522. [Crossref]
43. Mittelman, A., Chen, Z.J., Liu, C.C., Hirai, S. and Ferrone, S. (1994) Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse anti-idiotypic monoclonal antibody MK2-23. Cancer Res., 54: 415-421. [PubMed]
44. Coelho, M., Gauthier, P., Pugniere, M., Roquet, F., Pelegrin1, A. and Navarro-Teulon, I. (2004) Isolation and characterization of a human anti-idiotypicscFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice. Br. J. Cancer, 90: 2032-2041. [Crossref] [PubMed] [PMC]
45. Lee, G. and Ge, B. (2010) Inhibition of in vitro tumor cell growth by RP215 monoclonal antibody and antibodies raised against its anti-idiotype antibodies. Cancer Immunol. Immunother., 59(9): 1347-1356. [Crossref] [PubMed]
47. Railo, M., Lundin, J., Haglund, C., Von Smitten, K., von Boguslawsky, K. and Nordling, S. (2006) Ki-67, p53, ER receptors, ploidy and S phase as long-term prognostic factors in T1 non denegative breast cancer. Tumor Biol., 1: 45-51.
48. Uttenreuther-Fischer, M.M., Kruger, J.A. and Fischer, P. (2006) Molecular characterization of the anti-idiotypic immune response of a relapse-free neuroblastoma patient following antibody therapy: A possible vaccine against tumors of neuroectodermal origin? J. Immunol., 176: 7775-7786. [Crossref] [PubMed]
50. Stanglmaier, M., Reis, S. and Hallek, M. (2007) Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann. Hematol., 83: 634-645.
51. Kunpeng, Z., Yugang, W., Jugao, C., Yan, L., Beifen, S. and Yuanfang, M. (2009) The construction and expression of a novel chimeric anti-DR5 antibody. Hybridoma (Larchmt), 28: 101-105. [Crossref] [PubMed]
52. Nakano, K., Orita, T., Nezu, J., Yoshino, T., Ohizumi, I., Sugimoto, M., Furugaki, K., Kinoshita, Y., Ishiguro, T., Hamakubo, T., Kodama, T., Aburatani, H., Yamada-Okabe, H. and Tsuchiya, M. (2009) Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun., 378: 279-284. [Crossref] [PubMed]
53. Ragupathi, G., Liu, N.X., Musselli, C., Powell, S., Lloyd, K. and Livingston, P.O. (2005) Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J. Immunol., 174: 5706-5712. [Crossref] [PubMed]
54. Song, J.S., Sainz, I.M., Cosenza, S.C., Isordia-Salas, I., Bior, A., Bradford, H.N., Guo, Y.L., Pixley, R.A., Reddy, E.P. and Colman, R.W. (2004) Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. Blood, 104: 2065-2072. [Crossref] [PubMed]
55. Trauth, B.C., Klas, C., Peters, A.M.J., Matzku, S., Moller, P., Falk, W., Debatin, K.M. and Krammer, P.H. (1989) Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science, 245: 301-305. [Crossref] [PubMed]
56. Caton, A.J., Herlyn, D., Ross, A.H., Koprowski, H. and Identical, D. (1990) Region sequences expressed by murine monoclonal antibodies specific for a human tumor-associated antigen. J. Immunol., 144: 1965-1968. [PubMed]57. Metheringham, R.L., Pudney, V.A., Gunn, B., Towey, M., Spendlove, I. and Durrant, L.G. (2009) Antibodies designed as effective cancer vaccines. MAbs, 1: 71-85. [Crossref] [PubMed] [PMC]